S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
pixel
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
pixel
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
pixel
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
pixel
Log in
NASDAQ:NRC

National Research Stock Forecast, Price & News

$47.97
-0.34 (-0.70 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$47.14
Now: $47.97
$48.10
50-Day Range
$42.75
MA: $45.90
$48.83
52-Week Range
$34.00
Now: $47.97
$70.59
Volume33,169 shs
Average Volume35,278 shs
Market Capitalization$1.21 billion
P/E Ratio32.63
Dividend YieldN/A
Beta0.66
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provide actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions; and health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.

MarketRank

Overall MarketRank

0.63 out of 5 stars

Business Services Sector

292nd out of 440 stocks

Commercial Physical Research Industry

23rd out of 42 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
Current SymbolNASDAQ:NRC
CUSIPN/A
Phone402-475-2525
Employees464
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$127.98 million
Cash Flow$1.61 per share
Book Value$1.32 per share

Profitability

Net Income$32.41 million

Miscellaneous

Market Cap$1.21 billion
Next Earnings Date2/9/2021 (Estimated)
OptionableNot Optionable
$47.97
-0.34 (-0.70 %)
(As of 01/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NRC News and Ratings via Email

Sign-up to receive the latest news and ratings for NRC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











National Research (NASDAQ:NRC) Frequently Asked Questions

How has National Research's stock price been impacted by Coronavirus?

National Research's stock was trading at $52.18 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NRC shares have decreased by 8.1% and is now trading at $47.97.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than National Research?

Wall Street analysts have given National Research a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but National Research wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Michael D. Hays' approval rating as National Research's CEO?

85 employees have rated National Research CEO Michael D. Hays on Glassdoor.com. Michael D. Hays has an approval rating of 87% among National Research's employees.

When is National Research's next earnings date?

National Research is scheduled to release its next quarterly earnings announcement on Tuesday, February 9th 2021.
View our earnings forecast for National Research
.

How were National Research's earnings last quarter?

National Research Co. (NASDAQ:NRC) issued its earnings results on Tuesday, November, 3rd. The company reported $0.37 earnings per share for the quarter. The business had revenue of $33.48 million for the quarter. National Research had a net margin of 28.79% and a trailing twelve-month return on equity of 87.53%.
View National Research's earnings history
.

How often does National Research pay dividends? What is the dividend yield for National Research?

National Research announced a quarterly dividend on Wednesday, March 11th. Shareholders of record on Tuesday, March 31st will be given a dividend of $0.21 per share on Wednesday, April 15th. This represents a $0.84 annualized dividend and a yield of 1.75%. The ex-dividend date is Monday, March 30th.
View National Research's dividend history
.

Are investors shorting National Research?

National Research saw a increase in short interest in December. As of December 31st, there was short interest totaling 292,200 shares, an increase of 44.9% from the December 15th total of 201,600 shares. Based on an average trading volume of 31,300 shares, the short-interest ratio is presently 9.3 days. Currently, 2.2% of the shares of the stock are short sold.
View National Research's Short Interest
.

Who are some of National Research's key competitors?

What other stocks do shareholders of National Research own?

Based on aggregate information from My MarketBeat watchlists, some companies that other National Research investors own include Altria Group (MO), Enterprise Products Partners (EPD), AbbVie (ABBV), Dominion Energy (D), Gilead Sciences (GILD), Pfizer (PFE), The Toronto-Dominion Bank (TD), Verizon Communications (VZ), Wells Fargo & Company (WFC) and TD Ameritrade (AMTD).

Who are National Research's key executives?

National Research's management team includes the following people:
  • Mr. Michael D. Hays, Founder, CEO, Pres & Director (Age 65, Pay $178.99k)
  • Mr. Kevin R. Karas CPA, CPA, Sr. VP of Fin., CFO, Treasurer & Sec. (Age 62, Pay $397.26k)
  • Ms. Helen Hrdy, Chief Growth Officer
  • Linda Stacy, VP of Fin.
  • Megan Charko, Sr. Mang. of Content Marketing

What is National Research's stock symbol?

National Research trades on the NASDAQ under the ticker symbol "NRC."

How do I buy shares of National Research?

Shares of NRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is National Research's stock price today?

One share of NRC stock can currently be purchased for approximately $47.97.

How big of a company is National Research?

National Research has a market capitalization of $1.21 billion and generates $127.98 million in revenue each year. National Research employs 464 workers across the globe.

What is National Research's official website?

The official website for National Research is www.nrchealth.com.

How can I contact National Research?

National Research's mailing address is 1245 Q STREET, LINCOLN NE, 68508. The company can be reached via phone at 402-475-2525.

This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.